See more : Finolex Industries Limited (FINPIPE.NS) Income Statement Analysis – Financial Results
Complete financial analysis of ASKA Pharmaceutical Holdings Co.,Ltd. (4886.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ASKA Pharmaceutical Holdings Co.,Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Türkiye Petrol Rafinerileri A.S. (TUPRS.IS) Income Statement Analysis – Financial Results
- Danske Invest Nordiske Virksomhedsobligationer Akk KL (DKINVO.CO) Income Statement Analysis – Financial Results
- RADA Electronic Industries Ltd. (RADA) Income Statement Analysis – Financial Results
- Transcontinental Inc. (TCL-A.TO) Income Statement Analysis – Financial Results
- Party City Holdco Inc. (PRTY) Income Statement Analysis – Financial Results
ASKA Pharmaceutical Holdings Co.,Ltd. (4886.T)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.aska-pharma-hd.co.jp
About ASKA Pharmaceutical Holdings Co.,Ltd.
ASKA Pharmaceutical Holdings Co.,Ltd., through its subsidiaries, engages in the pharmaceutical, animal health, and hormone testing businesses in Japan. The company researches, develops, manufactures, and markets pharmaceutical products in the areas of endocrinology, obstetrics and gynecology, and urology; and manufactures, sells, imports, and exports veterinary medicines, veterinary medical devices, feed and feed additives, reagents, agrochemicals, industrial chemicals, hygiene products, and food products and their raw materials. It is also involved in the clinical examination and biological testing activities; and offers medical devices. The company was founded in 1920 and is headquartered in Tokyo, Japan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 62.84B | 60.46B | 56.61B | 55.18B | 52.54B | 46.71B | 48.94B | 48.53B | 43.22B | 42.91B | 39.50B | 40.96B |
| Cost of Revenue | 32.18B | 31.88B | 30.26B | 29.80B | 28.53B | 27.81B | 30.06B | 29.61B | 26.07B | 25.71B | 22.43B | 23.05B |
| Gross Profit | 30.67B | 28.59B | 26.35B | 25.38B | 24.02B | 18.89B | 18.89B | 18.91B | 17.14B | 17.19B | 17.07B | 17.91B |
| Gross Profit Ratio | 48.80% | 47.28% | 46.55% | 46.00% | 45.71% | 40.45% | 38.58% | 38.97% | 39.67% | 40.07% | 43.21% | 43.72% |
| Research & Development | 4.73B | 4.23B | 3.60B | 0.00 | 4.91B | 4.49B | 4.06B | 4.97B | 4.17B | 4.03B | 4.14B | 4.27B |
| General & Administrative | 13.13B | 13.16B | 12.19B | 0.00 | 11.60B | 11.73B | 11.04B | 11.14B | 10.78B | 10.69B | 11.11B | 11.32B |
| Selling & Marketing | 6.31B | 6.09B | 5.77B | 0.00 | 5.99B | 885.00M | 963.00M | 1.01B | 1.02B | 1.05B | 1.10B | 1.26B |
| SG&A | 19.44B | 19.25B | 17.96B | 21.77B | 17.60B | 12.61B | 12.01B | 12.15B | 11.80B | 11.74B | 12.21B | 12.58B |
| Other Expenses | 1.00M | -67.00M | -73.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 24.17B | 23.48B | 21.56B | 21.77B | 22.51B | 17.11B | 16.06B | 17.12B | 15.98B | 15.66B | 16.28B | 16.42B |
| Cost & Expenses | 56.34B | 55.35B | 51.81B | 51.57B | 51.03B | 44.92B | 46.12B | 46.73B | 42.05B | 41.37B | 38.71B | 39.48B |
| Interest Income | 4.00M | 288.00M | 202.00M | 178.00M | 164.00M | 179.00M | 174.00M | 229.00M | 184.00M | 150.00M | 151.00M | 107.00M |
| Interest Expense | 40.00M | 50.00M | 56.00M | 59.00M | 64.00M | 41.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.66B | 3.13B | 2.89B | 3.36B | 3.76B | 2.62B | 2.39B | 2.50B | 2.06B | 1.82B | 2.46B | 2.43B |
| EBITDA | 12.57B | 8.24B | 7.68B | 6.97B | 5.27B | 4.40B | 5.22B | 4.30B | 3.22B | 3.53B | 3.43B | 4.05B |
| EBITDA Ratio | 20.00% | 14.00% | 13.89% | 12.63% | 10.03% | 9.43% | 10.66% | 8.85% | 7.46% | 7.52% | 8.00% | 8.50% |
| Operating Income | 6.50B | 5.11B | 4.80B | 3.61B | 1.51B | 1.78B | 2.83B | 1.79B | 1.17B | 1.41B | 702.00M | 1.05B |
| Operating Income Ratio | 10.34% | 8.45% | 8.47% | 6.54% | 2.87% | 3.82% | 5.77% | 3.70% | 2.70% | 3.29% | 1.78% | 2.56% |
| Total Other Income/Expenses | 3.36B | 249.00M | 1.37B | -35.00M | -607.00M | 100.00M | 239.00M | 1.51B | 282.00M | 278.00M | 245.00M | 545.00M |
| Income Before Tax | 9.86B | 5.36B | 6.16B | 3.58B | 901.00M | 1.88B | 3.06B | 3.30B | 1.45B | 1.69B | 946.00M | 1.59B |
| Income Before Tax Ratio | 15.69% | 8.86% | 10.89% | 6.48% | 1.71% | 4.03% | 6.26% | 6.80% | 3.35% | 3.93% | 2.39% | 3.89% |
| Income Tax Expense | 2.32B | 1.12B | 1.87B | 861.00M | 252.00M | 138.00M | 674.00M | 356.00M | 747.00M | 530.00M | 421.00M | 482.00M |
| Net Income | 7.55B | 4.24B | 4.29B | 2.71B | 649.00M | 1.74B | 2.39B | 2.94B | 701.00M | 1.19B | 495.00M | 1.11B |
| Net Income Ratio | 12.01% | 7.01% | 7.58% | 4.92% | 1.24% | 3.73% | 4.88% | 6.07% | 1.62% | 2.78% | 1.25% | 2.72% |
| EPS | 266.49 | 150.08 | 151.22 | 95.63 | 22.94 | 61.80 | 84.77 | 105.37 | 25.14 | 42.86 | 17.82 | 40.27 |
| EPS Diluted | 266.49 | 150.08 | 151.22 | 95.63 | 22.94 | 61.80 | 84.77 | 105.37 | 25.14 | 42.86 | 17.82 | 40.27 |
| Weighted Avg Shares Out | 28.31M | 28.24M | 28.37M | 28.37M | 28.29M | 28.22M | 28.17M | 27.94M | 27.89M | 27.83M | 27.77M | 27.66M |
| Weighted Avg Shares Out (Dil) | 28.31M | 28.24M | 28.37M | 28.37M | 28.29M | 28.22M | 28.17M | 27.94M | 27.89M | 27.83M | 27.77M | 27.66M |
Source: https://incomestatements.info
Category: Stock Reports